Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer

Colorectal cancer (CRC) remains one of the deadliest malignancies worldwide despite recent progress in treatment strategies. Though immune checkpoint inhibition has proven effective for a number other tumors, it offers benefits only small group CRC patients with high microsatellite instability. In general, heterogenous cell groups tumor microenvironment are considered as major barrier unveiling causes low response. Therefore, deconvolution cellular components highly heterogeneous microenvironments is crucial understanding contexture cancer. this review, we assimilate current knowledge and studies examining anti-tumor immunity CRC. We also discuss utilization novel assessment methods that have not been used research to date.